Your browser doesn't support javascript.
loading
Sebaceous Carcinoma of the Face Treated With Mohs Micrographic Surgery.
Meer, Elana; Nguyen, Brian; Luna, Gabriela L; Kim, Diana; Bautista, Sana; McGeehan, Brendan; Giordano, Cerrene; Etzkorn, Jeremy; Miller, Christopher; Briceño, César A.
Afiliação
  • Meer E; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Nguyen B; Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Luna GL; Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Kim D; Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Bautista S; Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
  • McGeehan B; Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Giordano C; Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Etzkorn J; Center for Preventative Ophthalmology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Miller C; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Briceño CA; Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
Dermatol Surg ; 48(11): 1148-1154, 2022 11 01.
Article em En | MEDLINE | ID: mdl-36194726
BACKGROUND: Mohs micrographic surgery (MMS) for sebaceous carcinoma (SC) may reduce local recurrence rates, but published case series have small cohorts and limited follow-up. Mohs micrographic surgery is particularly suitable for sensitive functional and cosmetic locations, such as the face, because it facilitates tissue conservation using complete peripheral and deep margin assessment before reconstruction. Coordinated care between Mohs and oculoplastic surgeons has not been described. OBJECTIVE: To assess rates of local recurrence and metastasis after MMS of facial SC and to describe coordinated care between Mohs and oculoplastic surgeons. MATERIALS AND METHODS: Retrospective review identified facial SC cases treated with MMS at a single institution from January 2005 to August 2020. Tumor characteristics and outcomes were recorded. Descriptive and predictive analyses were performed. RESULTS: Forty-nine cases were reviewed with a mean follow-up of 51 months. The most common sites were periorbital, infraorbital cheek, and nasal ala. No patients experienced regional recurrence after MMS. One patient with Muir-Torre syndrome developed metastatic recurrence (at 82.9 months). All patients underwent 2-stage reconstruction with dermatology-performed MMS and oculoplastic reconstruction. CONCLUSION: Collaboration between Mohs and oculoplastic surgeons with a tissue-sparing approach of MMS can reduce recurrence and optimize cosmesis and function for central facial SC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Sebáceas / Cirurgia de Mohs / Adenocarcinoma Sebáceo / Face Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Dermatol Surg Assunto da revista: DERMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Sebáceas / Cirurgia de Mohs / Adenocarcinoma Sebáceo / Face Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Dermatol Surg Assunto da revista: DERMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article